EMA reconsiders and gives its positive opinion for the approval of ixazomib
Ixazomib (Ninlaro®) has received a positive recommendation from the Committee for Human Medicinal Products (CHMP) within the European Medicines Agency (EMA) for its use in relapsed myeloma patients. The decision follows an initial negative CHMP recommendation that was appealed by the pharmaceutical company, Takeda.